Savara: A High-Risk Opportunity

Savara, Inc. (SVRA) shares have rebounded over 100% since receiving an FDA refuse-to-file letter for its sole clinical candidate, molgramostim, for aPAP, largely due to the company's alignment with the FDA on a Biologics License Application (BLA) resubmission. Molgramostim showed strong DLCO results in the IMPALA-2 trial, reducing the need for whole lung lavage and targeting a U.S. market exceeding $2 billion. Financially, Savara holds over $125 million in cash, recently raised $140 million, and analysts unanimously rate the stock a "buy," projecting $400 million in sales by 2030.

Analysis

Savara, Inc. (SVRA) shares have experienced a significant rebound, surging over 100% since receiving a refuse-to-file letter from the FDA in May 2025 for its sole clinical candidate, molgramostim. This strong recovery is attributed to the company's successful alignment with the FDA regarding a Biologics License Application (BLA) resubmission for the drug, which targets severe aPAP. The market's positive reaction underscores renewed confidence in molgramostim's path to approval.

Molgramostim demonstrated robust clinical efficacy, exhibiting strong DLCO results in the IMPALA-2 trial and notably reducing the need for whole lung lavage. This positions the drug to address a substantial U.S. market opportunity estimated to exceed $2 billion. The clinical data supports the potential for a significant revenue stream upon market entry.

Financially, Savara maintains a solid position with over $125 million in cash and recently completed a $140 million capital raise, providing ample liquidity for ongoing operations and development. Analyst sentiment is unanimously positive, with all analysts rating SVRA a "buy" and projecting substantial sales of $400 million by 2030. This strong financial backing and bullish analyst consensus further de-risk the investment thesis.

Key Decisions for Investors

• Monitor the progress and timeline of Savara's BLA resubmission for molgramostim, as regulatory approval remains a critical catalyst for future share performance.
• Evaluate the company's strong cash position and recent capital raise as supportive factors for continued development and potential commercialization efforts.
• Consider the significant $2 billion+ U.S. market opportunity for molgramostim and the unanimous analyst "buy" ratings, which project substantial sales growth by 2030.